|
Video: What is a Stock Split?
|
|
Tenax Therapeutics is focused on identifying, developing and commercializing late-stage pharmaceutical therapeutic products for cardiovascular and pulmonary diseases. Co. owns a license granting Life Newco, Inc., its wholly owned subsidiary, a sublicensable right to develop and commercialize pharmaceutical products containing levosimendan, 2.5 mg/ml concentrate for solution for infusion / 5ml vial in the U.S. and Canada. Co.'s programs include: Levosimendan, which is a calcium sensitizer/K-ATP activator developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib (marketed in the U.S. as Gleevec®), which is a tyrosine kinase inhibitor. According to our Tenax Therapeutics stock split history records, Tenax Therapeutics has had 3 splits. | |
|
Tenax Therapeutics (TENX) has 3 splits in our Tenax Therapeutics stock split history database. The first split for TENX took place on February 26, 2018. This was a 1 for 20 reverse split, meaning for each 20 shares of TENX owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 50 share position following the split. TENX's second split took place on January 05, 2023. This was a 1 for 20 reverse split, meaning for each 20 shares of TENX owned pre-split, the shareholder now owned 1 share. For example, a 50 share position pre-split, became a 2.5 share position following the split. TENX's third split took place on January 03, 2024. This was a 1 for 80 reverse split, meaning for each 80 shares of TENX owned pre-split, the shareholder now owned 1 share. For example, a 2.5 share position pre-split, became a 0.03125 share position following the split.
When a company such as Tenax Therapeutics conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the Tenax Therapeutics stock split history from start to finish, an original position size of 1000 shares would have turned into 0.03125 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Tenax Therapeutics shares, starting with a $10,000 purchase of TENX, presented on a split-history-adjusted basis factoring in the complete Tenax Therapeutics stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
04/25/2014 |
|
End date: |
04/23/2024 |
|
Start price/share: |
$160,320.00 |
|
End price/share: |
$3.50 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-100.00% |
|
Average Annual Total Return: |
-65.80% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$0.22 |
|
Years: |
10.00 |
|
|
|
Date |
Ratio |
02/26/2018 | 1 for 20 | 01/05/2023 | 1 for 20 | 01/03/2024 | 1 for 80 |
|
|